title: Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.
abstract: The association between dose intensity of chemotherapy with the rate of complete remission (CR), the duration of disease-free survival (DFS), and overall survival (OS) was separately analyzed for 67 patients initially treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), and for 75 patients in relapse following radiotherapy who had received MOPP as a salvage regimen. In both groups of patients, the fraction of the total dose of mechlorethamine delivered in all cycles divided by the planned dose for six cycles was strongly associated with OS (P = .002 for patients receiving initial MOPP and P = .02 for the salvage group, respectively). B symptoms were independent of drug-derived variables associated with OS (corresponding P values .03 for initial MOPP and .004 for the salvage group). The predictive value of mechlorethamine dosage with regard to OS was retained in an analysis restricted to the patients receiving greater than or equal to six cycles of chemotherapy. In the initial chemotherapy group, mechlorethamine dosage was associated with attainment of CR but none of the variables tested was predictive of DFS. In the salvage chemotherapy group, mechlorethamine dosage was associated with attainment of CR and duration of DFS as well. The results emphasize that, besides tumor characteristics, optimal dosage of chemotherapy is of great importance for survival.
authors.affiliation: Department of Internal Medicine, University Hospital of Nijmegen, The Netherlands.
authors.forename: R E
authors.initials: RE
authors.lastname: van Rijswijk
authors.forename: C
authors.initials: C
authors.lastname: Haanen
authors.forename: A W
authors.initials: AW
authors.lastname: Dekker
authors.forename: A J
authors.initials: AJ
authors.lastname: de Meijer
authors.forename: J
authors.initials: J
authors.lastname: Verbeek
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001799:Blood Sedimentation; D016002:Discriminant Analysis; D004305:Dose-Response Relationship, Drug; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies; D012044:Regression Analysis; D013156:Splenectomy; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D007770:L-Lactate Dehydrogenase; D011241:Prednisone